176 related articles for article (PubMed ID: 31843543)
1. Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma.
Mian H; Fiala M; Wildes TM
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):98-104.e1. PubMed ID: 31843543
[TBL] [Abstract][Full Text] [Related]
2. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
3. Use of bone-modifying agents and clinical outcomes in older adults with multiple myeloma.
Olszewski AJ; Barth PM; Reagan JL
Cancer Med; 2019 Nov; 8(16):6945-6954. PubMed ID: 31566898
[TBL] [Abstract][Full Text] [Related]
4. Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
Palumbo A; Hajek R; Delforge M; Kropff M; Petrucci MT; Catalano J; Gisslinger H; Wiktor-Jędrzejczak W; Zodelava M; Weisel K; Cascavilla N; Iosava G; Cavo M; Kloczko J; Bladé J; Beksac M; Spicka I; Plesner T; Radke J; Langer C; Ben Yehuda D; Corso A; Herbein L; Yu Z; Mei J; Jacques C; Dimopoulos MA;
N Engl J Med; 2012 May; 366(19):1759-69. PubMed ID: 22571200
[TBL] [Abstract][Full Text] [Related]
5. Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry.
Rifkin RM; Jagannath S; Durie BGM; Narang M; Terebelo HR; Gasparetto CJ; Toomey K; Hardin JW; Wagner L; Parikh K; Abouzaid S; Srinivasan S; Kitali A; Zafar F; Abonour R
Clin Ther; 2018 Jul; 40(7):1193-1202.e1. PubMed ID: 30007443
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulator adherence in multiple myeloma patients with lower socioeconomic status: a retrospective study.
Ononogbu O; Akindele O; Yazdanfard S; Fatima B; Abughosh S; Trivedi MV
Support Care Cancer; 2024 Jun; 32(7):407. PubMed ID: 38833106
[TBL] [Abstract][Full Text] [Related]
7. Association of High-Deductible Health Plan Enrollment With Spending on and Use of Lenalidomide Therapy Among Commercially Insured Patients With Multiple Myeloma.
Jazowski SA; Wilson L; Dusetzina SB; Zafar SY; Zullig LL
JAMA Netw Open; 2022 Jun; 5(6):e2215720. PubMed ID: 35671056
[TBL] [Abstract][Full Text] [Related]
8. Adherence to immunomodulatory drugs in patients with multiple myeloma.
Cransac A; Aho S; Chretien ML; Giroud M; Caillot D; Boulin M
PLoS One; 2019; 14(3):e0214446. PubMed ID: 30917164
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
[TBL] [Abstract][Full Text] [Related]
10. Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide.
Schoenbeck KL; Wildes TM
Clin Interv Aging; 2020; 15():619-633. PubMed ID: 32440105
[TBL] [Abstract][Full Text] [Related]
11. Second primary malignancy among older adults with multiple myeloma receiving first-line lenalidomide-based therapy: A population-based analysis.
Giri S; Barth P; Costa LJ; Olszewski AJ
J Geriatr Oncol; 2021 Mar; 12(2):256-261. PubMed ID: 32684352
[TBL] [Abstract][Full Text] [Related]
12. Adherence to and effectiveness of lenalidomide after 1 year of treatment in a real world setting.
Santoleri F; Lasala R; Ranucci E; Rocchi M; Pulini S; Morelli AM; Spadano A; Costantini A
J Oncol Pharm Pract; 2022 Jan; 28(1):24-30. PubMed ID: 33349148
[TBL] [Abstract][Full Text] [Related]
13. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma.
Zweegman S; van der Holt B; Mellqvist UH; Salomo M; Bos GM; Levin MD; Visser-Wisselaar H; Hansson M; van der Velden AW; Deenik W; Gruber A; Coenen JL; Plesner T; Klein SK; Tanis BC; Szatkowski DL; Brouwer RE; Westerman M; Leys MR; Sinnige HA; Haukås E; van der Hem KG; Durian MF; Mattijssen EV; van de Donk NW; Stevens-Kroef MJ; Sonneveld P; Waage A
Blood; 2016 Mar; 127(9):1109-16. PubMed ID: 26802176
[TBL] [Abstract][Full Text] [Related]
14. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
Chari A; Parikh K; Ni Q; Abouzaid S
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):645-655. PubMed ID: 31377207
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
[TBL] [Abstract][Full Text] [Related]
16. Role of Patient Characteristics and Insurance Type in Newly Diagnosed Multiple Myeloma Care Disparities.
Gasoyan H; Anwer F; Casacchia NJ; Kovach JD; Valent J; Wang M; Halpern MT; Rothberg MB
JCO Oncol Pract; 2024 May; 20(5):699-707. PubMed ID: 38354331
[TBL] [Abstract][Full Text] [Related]
17. Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis.
Chakraborty R; Bin Riaz I; Malik SU; Marneni N; Mejia Garcia A; Anwer F; Khorana AA; Rajkumar SV; Kumar S; Murad MH; Wang Z; Khan SU; Majhail NS
Cancer; 2020 Apr; 126(8):1640-1650. PubMed ID: 31913498
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; Corral LL; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Arguiñano JM; Quintana N; García JL; Bladé J; Lahuerta JJ; Miguel JS
Lancet Oncol; 2016 Aug; 17(8):1127-1136. PubMed ID: 27402145
[TBL] [Abstract][Full Text] [Related]
19. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
Palumbo A; Falco P; Corradini P; Falcone A; Di Raimondo F; Giuliani N; Crippa C; Ciccone G; Omedè P; Ambrosini MT; Gay F; Bringhen S; Musto P; Foà R; Knight R; Zeldis JB; Boccadoro M; Petrucci MT;
J Clin Oncol; 2007 Oct; 25(28):4459-65. PubMed ID: 17785703
[TBL] [Abstract][Full Text] [Related]
20. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
